UNITED FOR HD

Roche has announced the discontinuation of huntingtin-lowering drugs tominersen and RG649 based on independent, data-driven decisions. The Phase 2 study GENERATION HD2 evaluated tominersen in Huntington disease (HD) and enrolled 301 participants across 15 countries, including Canada. The POINT-HD study, a first-in-human study of RG6496 in HD, was open internationally, with planned expansion into Canada. This study will no longer take place. We recognize that this may still be disappointing news and encourage you to access support. Please reach out to your Family Services team member for assistance.

Prilenia and Ferrer have announced the launch of a Phase 3 clinical study of pridopidine in Huntington disease (HD). The first U.S. sites are expected to open for enrollment in June 2026, with sites in Europe, the UK, and Canada to follow. This study will add to a growing body of clinical research on pridopidine in HD; previous trials did not meet their primary endpoints. Canadian study sites have not yet been confirmed, but more information will be provided once available.